13 July 2023
Latham & Watkins Advises 4D Molecular Therapeutics in License Agreement With Astellas Pharma
Advising firms
Deal team
2 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Chris Hazuka Lead | Latham & Watkins LLP | Partner | Healthcare & Life Sciences | Bay Area |
| Mark Roeder Lead | Latham & Watkins LLP | Partner | Healthcare & Life Sciences | Bay Area |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- 4D Molecular Therapeutics, Inc.Other
- Counterparties
- Astellas Pharma Inc. (Other)